Q2 2022 Camurus AB Earnings Call Transcript
Good day, and welcome to the Camurus Q2 2022 Earnings Conference Call. (Operator Instructions) Please note, this event is being recorded.
I would now like to turn the conference over to Fredrik Tiberg. Please go ahead.
()- -
Thank you so much, and hello, everybody. Thank you for taking the time to joining us this Friday afternoon for our second quarter earnings call. It's a pleasure to update you on the continued progress of Camurus.
Please note our forward-looking statements. And this is today's agenda. With me on the call is Jon Garay, our Chief Financial Officer; and on the phone from Cambridge, U.K., is Richard Jameson, our Chief Commercial Officer.
Before going to highlights, here is a snapshot of Camurus 3 years after the approval and launch of our first transformative medicine, Buvidal. We have gone far proven our commercial execution ability and emerged as a leader in the opioid dependence treatment field, advanced our late
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |